Related by context. All words. (Click for frequent words.) 72 NKTR 71 INGN 70 ARRY 70 ITMN 69 AEGR 67 ATHX 67 histone deacetylase HDAC inhibitor 67 ACHN 67 IMMU 66 ALTU 66 preclinical efficacy 66 CRx 66 Bezielle 66 Perifosine 66 ISIS # 65 CUDC 65 ALKS 65 PS# [001] 65 polymerase inhibitor 65 MORAb 65 ganetespib 65 HCV protease inhibitor 65 HDAC Inhibitor 64 Carfilzomib 64 targeting CD# 64 perifosine 64 liposomal formulation 64 pan HDAC inhibitor 64 ENMD 64 MT# MEDI 63 mertansine 63 Traficet EN 63 Phase 2a trial 63 PCK# 63 phase IIb clinical 63 HGS ETR1 63 Phase 1b clinical 63 oral prodrug 63 huC# DM4 63 CD# antibody [001] 63 JAK inhibitor 63 Phase Ib clinical 63 Phase IIa clinical 63 Debio 63 investigational compound 63 seliciclib 63 Phase 1b 63 Triolex 63 RDEA# 62 ATL# [001] 62 PEG SN# 62 Phase Ib 62 VQD 62 Ozarelix 62 Archexin 62 MEK inhibitor 62 non nucleoside inhibitor 62 orally bioavailable 62 SCH # 62 PRTX 62 RGB # 62 INCB# [001] 62 4SC 62 JAK1 62 Azedra 62 KRN# 62 histone deacetylase inhibitor 62 CCR5 antagonist 62 telaprevir VX 62 Mipomersen 62 preclinical studies 62 Alpharadin 62 Aurora kinase 62 favorable pharmacokinetic profile 62 investigational humanized monoclonal antibody 62 rNAPc2 62 PXD# 62 CEQ# 61 Aplidin 61 MEDI 61 Pharmacokinetics PK 61 inhibitor RG# 61 YONDELIS 61 talactoferrin 61 lintuzumab 61 Sym# 61 BPAX 61 oral FTY# 61 OncoVEX GM CSF 61 humanized monoclonal antibody 61 compound AEZS 61 HuMax CD4 61 Factor VIIa 61 PF # [001] 61 humanized anti 61 Æterna Zentaris 61 Phase Ib clinical trials 61 Tarvacin 61 MGCD# [001] 61 kinase inhibitor 61 Phase IIa trial 61 Hsp# inhibitor 61 PSN# [002] 61 CIMZIA TM 61 antiviral activity 61 ADXS# 61 CCX# 61 Cethromycin 61 Amrubicin 61 elotuzumab 61 enzastaurin 61 alvespimycin 61 CR# vcMMAE 61 Tesmilifene 61 Enzastaurin 60 nucleoside analog 60 CYC# 60 Phase 2b 60 iCo 60 orally administered inhibitor 60 glufosfamide 60 HCV protease 60 PDE4 inhibitor 60 HCV protease inhibitors 60 RVX 60 OXi# 60 PARP inhibitor 60 radezolid 60 Arqule 60 ELACYT 60 axitinib 60 Aflibercept 60 novel histone deacetylase 60 Seattle Genetics SGEN 60 HuMax EGFr 60 Phase 2a clinical 60 Tarceva TM 60 Phase Ib study 60 Phase 2a 60 HQK 60 oral Hsp# inhibitor 60 Zoraxel 60 selective kinase inhibitor 60 solithromycin 60 sodium glucose cotransporter 60 phase IIa clinical 60 IFN α 60 Virulizin ® 60 Xanafide 60 dacetuzumab 60 Phase IIb clinical 60 ON #.Na 60 Immunomedics Inc 60 CA4P 60 #th Annual Interscience 60 Guanilib 60 Apoptone 60 Anticalin R 60 Ceflatonin 60 Vidofludimus 60 Exelixis XL# 60 thymalfasin 60 MGCD# [002] 60 Laquinimod 60 BAY #-# 60 CYTR 60 AEG# 60 depsipeptide 60 xenograft models 60 Pharmacokinetic PK 60 tanespimycin 60 otelixizumab 60 velafermin 60 EOquin 60 HCV NS5B polymerase 60 Phase Ib II 60 multi kinase inhibitor 60 celgosivir 60 preclinically 59 Zybrestat 59 OPXA 59 SPC# [001] 59 MEK inhibitors 59 fosbretabulin 59 HDAC inhibitor 59 DermaVir Patch 59 antisense drug 59 sunitinib malate 59 ZACTIMA 59 preclinical 59 CYT# 59 elacytarabine 59 metastatic renal cell carcinoma 59 NBIX 59 ixabepilone 59 Rexahn Pharmaceuticals 59 AQ4N 59 XL# [003] 59 selective agonist 59 rilonacept 59 Bavituximab 59 FOLOTYN ® 59 IDX# 59 Harbor BioSciences 59 virus HCV protease inhibitor 59 TELINTRA 59 milatuzumab 59 Epidermal Growth Factor Receptor 59 XmAb# 59 Kinase Inhibitor 59 BMN 59 ENMD # 59 picoplatin 59 vascular disrupting agent 59 mapatumumab 59 Daclizumab 59 CoFactor 59 Omacetaxine 59 CD3 monoclonal antibody 59 EZN 59 Fc fusion protein 59 Panzem 59 SRT# [003] 59 antitumor activity 59 FLT3 59 ruxolitinib 59 obatoclax 59 ARQ 59 KSP inhibitor 59 anticancer compound 59 Azixa 59 DVAX 59 MDVN 59 small molecule inhibitor 59 NASDAQ AEZS 59 EpCAM 59 EndoTAG TM -1 59 ONTY 59 belinostat 59 Sapacitabine 59 Irinotecan 59 ZIOP 59 BZL# 59 Alocrest 59 Entremed 59 investigational drug 59 TG# [001] 59 elvucitabine 59 Immunogen 59 proteasome inhibitor 59 Virulizin R 59 brostallicin 59 Phase #b/#a clinical 59 oral ridaforolimus 59 Allovectin 7 59 protein kinase inhibitor 59 INCB# [002] 59 antibody MT# 59 Akt inhibitor 59 lumiliximab 59 decitabine 59 CCR9 59 pharmacokinetic PK 59 teriflunomide 59 Phase 2b clinical 59 CORT # 59 neratinib 59 Marqibo 59 Voreloxin 59 Dapagliflozin 59 LymphoStat B TM 59 Cloretazine ® 59 RhuDex ® 59 Pimavanserin 59 mTOR inhibitor 59 PRT# 59 Maribavir 59 CIMZIA ™ 59 anti leukemic 59 seliciclib CYC# 59 angiogenesis inhibitor 59 Tyrima 59 MAGE A3 ASCI 59 pomalidomide 59 ATL/TV# 59 PROSTVAC TM 59 pradefovir 59 trastuzumab emtansine T DM1 59 sorafenib tablets 59 HER2 positive metastatic breast 59 MLN# 59 phase IIb trial 59 phase IIb 59 placebo controlled Phase 59 IMGN 59 ANG# 59 Ardea Biosciences 58 investigational compounds 58 Keryx Biopharmaceuticals 58 metastatic castration resistant 58 Radezolid 58 ocrelizumab 58 ASA# 58 Silodosin 58 MAP# 58 ThGRF 58 SGMO 58 HCV replicon 58 AUXL 58 vinca alkaloid 58 INC# 58 PEG Interferon lambda 58 hematological cancers 58 Epothilone D 58 IMGN# 58 Everolimus 58 ONXX 58 HSP# inhibitor 58 HuLuc# 58 ELND# 58 teduglutide 58 HspE7 58 NXL# 58 mRCC 58 CRXX 58 gefitinib Iressa 58 oral proteasome inhibitor 58 voreloxin 58 CERE 58 Phase #/#a trial 58 GRN#L 58 NS4A 58 vidofludimus 58 KERX 58 viral kinetics 58 HRPC 58 LibiGel ® 58 Symadex 58 OMP #M# 58 antibody MAb 58 Pazopanib 58 Vion Pharmaceuticals 58 pertuzumab 58 RXII 58 TRX1 58 JAK2 inhibitor 58 receptor tyrosine kinase inhibitor 58 phase Ib 58 PI3K inhibitor 58 BiTE 58 ASCO abstract 58 oral antiviral 58 LY# [002] 58 BAL# [002] 58 Ocrelizumab 58 Blinatumomab 58 IDIX 58 Randomized Phase 58 Proxinium TM 58 anti amnesic 58 IPL# 58 Phase 1a clinical 58 integrase inhibitor 58 sorafenib Nexavar 58 Peregrine Pharmaceuticals 58 relapsed refractory multiple myeloma 58 nucleotide analog 58 Epratuzumab 58 Reverset 58 adecatumumab 58 R roscovitine 58 potent inhibitor 58 Phase 2b study 58 Serdaxin 58 selective modulator 58 delta isoform 58 CCR9 antagonist 58 Protexia R 58 Cetrorelix 58 TREANDA 58 XL# XL# 58 Elagolix 58 HGS ETR2 58 BiTE antibody 58 RP# [002] 58 phase IIa 58 targeted radiotherapeutic 58 IMC A# 58 SAR# [004] 58 Cloretazine 58 Luteinizing Hormone Releasing Hormone 58 GALNS 58 PSMA ADC 58 Hsp# Inhibitor 58 AACR NCI EORTC 58 JAK3 58 GRN# 58 Pralatrexate 58 huN# DM1 58 BCIRG 58 bevacizumab Avastin ® 58 Phase IIa trials 58 AAG geldanamycin analog 58 Antiviral Activity 58 bendamustine 58 Phase Ia 58 Bicifadine 58 ALN TTR# 58 triphendiol 58 selective inhibitor 58 LymphoStat B 58 AKT inhibitor 58 Exelixis EXEL 58 castrate resistant prostate cancer 58 registrational trial 58 Phase 2b trial 58 forodesine 58 Removab 58 epratuzumab 58 IRX 2 58 ongoing Phase 1b 58 davunetide intranasal AL 58 IL# PE#QQR 58 Acadia Pharmaceuticals ACAD 58 danoprevir 58 Aptivus ® 58 Tanespimycin 58 PROMACTA 58 MAb 58 Dacogen injection 58 LY# [003] 58 telbivudine 58 EndoTAG 58 phase 2a 58 trastuzumab Herceptin 58 tesmilifene 58 Posiphen 58 ProSavin 58 rhIL 7 58 AP# [003] 58 ritonavir boosted 58 Phase IIa 58 brivaracetam 58 bosutinib 58 Clevudine 58 Bafetinib 58 mitogen activated ERK kinase 58 alpha antagonist 58 Civacir 58 PKC# 58 CCR2 58 Onconase 58 HCV SPRINT 58 P#X# antagonist 58 Onalta 58 Peginterferon 58 BCX# 58 Bendavia 58 investigational oral 58 TRO# 58 Ridaforolimus 58 Golimumab 58 eprotirome 58 AEterna 58 cannabinor 57 EGFR HER2 57 Phase 2a Clinical Trial 57 Ziopharm 57 posaconazole 57 Nexavar ® 57 Boceprevir 57 eniluracil 57 BAL# [001] 57 Nasdaq OPTR 57 signal transduction inhibitor 57 Preclinical Data 57 nab paclitaxel 57 Oritavancin 57 Phase 2b Clinical Trial 57 tolerability profiles 57 selective androgen receptor modulator 57 tubulin inhibitor 57 multiple ascending dose 57 Nasdaq ACHN 57 crizotinib PF # 57 Ambrisentan 57 Actilon 57 SUVN 57 elagolix 57 Taxotere ® 57 phase IIb study 57 Velcade bortezomib 57 VEGF receptor 57 Capesaris 57 R#/MEM # 57 ADVEXIN 57 blinatumomab 57 atacicept 57 ataluren 57 GFT# 57 cilengitide 57 Regeneron Pharma 57 HuMax CD# 57 TKM ApoB 57 APOPTONE 57 BNC# 57 RhuDex R 57 AMEX ANX 57 INCB# [003] 57 OGXI 57 investigational monoclonal antibody 57 daclizumab 57 ADX# 57 Vandetanib 57 iniparib 57 Ceflatonin R 57 Phenoptin 57 XL# XL# XL# 57 nucleoside analogue 57 ZYBRESTAT 57 Tesetaxel 57 reversible inhibitor 57 Tezampanel 57 Vernakalant 57 TBC# 57 lintuzumab SGN 57 Vicinium TM 57 Keryx Biopharma 57 Romidepsin 57 OHR/AVR# 57 lexidronam injection 57 CBLB# 57 Initiate Phase 57 vascular disrupting agents 57 Amigal 57 immunomodulator 57 QLT# 57 Elocalcitol 57 Nanobody ® 57 Ecallantide 57 nitazoxanide 57 5 HT6 receptor 57 ALN TTR 57 polymerase inhibitors 57 CanAg 57 FTY# fingolimod 57 antisense oligonucleotide 57 ThermoDox R 57 ErbB2 positive 57 IKK epsilon 57 midstage clinical 57 ANAVEX #-# [003] 57 oral nucleoside analogue 57 Phase IIb Trial 57 ALN VSP 57 pharmacokinetic PK study 57 Preclinical studies 57 nonclinical studies 57 Janus kinase 57 XYOTAX TM 57 GLYX 57 selective antagonist 57 zanolimumab 57 HoFH 57 Dalbavancin 57 PNP inhibitor 57 imetelstat 57 CYT# potent vascular disrupting 57 INNO 57 farletuzumab 57 Denufosol 57 Fibrillex TM 57 #D#C# 57 LAF# 57 Apaziquone 57 alfa 2a 57 Restanza 57 EndoTAGTM 1 57 Phase 1b trial 57 RDEA 57 Vicriviroc 57 Panzem R NCD 57 Glufosfamide 57 NS#/#A protease 57 CTAP# Capsules 57 Talabostat 57 Varespladib 57 Quinamed 57 Fibrillex 57 Thiovir 57 Phase 1a 57 pharmacokinetic studies 57 hA# 57 GVAX 57 CD# monoclonal antibody 57 pharmacokinetics PK 57 ofatumumab 57 Telaprevir 57 Gleevec imatinib mesylate 57 Phase IIb 57 vemurafenib 57 anti CD3 57 Menerba 57 IMA# 57 ANX 57 alagebrium 57 Exelixis compounds 57 MRNA 57 maribavir 57 Insegia 57 Clinical Trial Results 57 darapladib 57 K ras mutations 57 non nucleoside 57 Nexavar sorafenib 57 HGSI 57 omacetaxine mepesuccinate 57 recurrent ovarian cancer 57 ularitide 57 CCX# B 57 relapsed multiple myeloma 57 tolerability profile 57 volociximab 57 Allovectin 7 R 57 BIBW 57 UPLYSO 56 Telatinib 56 novel peptide 56 fostamatinib 56 LCP Tacro 56 dose cohorts 56 Aurexis 56 CG# [003] 56 PEGylated Fab fragment 56 CD4 monoclonal antibody 56 compound ITMN 56 erlotinib Tarceva ® 56 MBRX 56 BioNumerik 56 orally dosed 56 EGFR inhibitors 56 PLK1 SNALP 56 epothilone 56 Immunomedics IMMU 56 IgG1 monoclonal antibody 56 entinostat 56 Nanobody 56 AEterna Zentaris 56 Bortezomib 56 ARQL 56 Protease Inhibitor 56 trastuzumab Herceptin R 56 Immunotherapeutic 56 Phase 1b clinical trials 56 CRLX# 56 GSK '# 56 dirucotide 56 TRIOLEX 56 refractory chronic lymphocytic 56 renin inhibitor 56 evaluating tivozanib 56 Trastuzumab 56 pharmacokinetic PK profile 56 castration resistant prostate cancer 56 dose escalation clinical 56 Troxatyl 56 ALN PCS 56 Satraplatin 56 hematological malignancies 56 Aurora Kinase 56 AVN# [001] 56 Eltrombopag 56 MNTX 56 Atiprimod 56 Vitaxin 56 Hsp# inhibitors 56 Ixempra 56 PDX pralatrexate 56 IAP inhibitors 56 romidepsin 56 GLP toxicology studies 56 TH# [003] 56 Valopicitabine 56 somatostatin analogue 56 cetrorelix 56 canakinumab 56 Annamycin 56 BMS# 56 AVNR 56 EOquin TM 56 Bapineuzumab 56 metaglidasen 56 S/GSK# 56 LymphoStat B belimumab 56 ORMD 56 valopicitabine 56 P#X# 56 tyrosine kinase inhibitor 56 ProLindac 56 systemic RNAi therapeutic 56 epithelial tumors 56 TMC# [002] 56 lomitapide 56 ozarelix 56 VitiGam 56 Pafuramidine 56 aflibercept 56 Copegus ribavirin 56 AVE# 56 EXEL 56 Pivotal Phase III 56 cytotoxic conjugate 56 DDP# 56 Bosutinib 56 rBChE 56 varespladib 56 pivotal Phase III 56 GAP #B# 56 NASDAQ VRTX 56 darinaparsin ZIO 56 interferon gamma 1b 56 BRAF inhibitor 56 Antisense 56 amrubicin 56 LUX Lung 56 interferon lambda 56 PPHM 56 Personalized Immunotherapy 56 trastuzumab DM1 T DM1 56 Phase IIb trials 56 oral kinase inhibitor 56 NOX E# 56 CLDX 56 GSK# [001] 56 Abiraterone acetate 56 Phase IIa clinical trials 56 #ME# 56 Pradefovir 56 LHRH antagonist 56 Meets Primary Endpoint 56 Thiarabine 56 metastatic colorectal 56 retaspimycin hydrochloride 56 ZFP Therapeutic 56 Synavive 56 AZILECT R 56 pharmacodynamic 56 PANC 56 registrational 56 Peregrine Pharma 56 Telbivudine 56 sapacitabine 56 Gleevec resistant 56 Phase 2b clinical trials 56 Targretin 56 LGND 56 prostate cancer AIPC 56 Erlotinib 56 methionine aminopeptidase 56 Idenix Pharmaceuticals 56 FTY# 56 metastatic castrate resistant 56 Pertuzumab 56 Neulasta ® 56 Darinaparsin 56 vesicular monoamine transporter 56 Panzem R 56 Interferon alfa 56 RG# [001] 56 GW# [003] 56 delafloxacin 56 VNP#M 56 Squalamine 56 ALXA 56 generation antisense 56 cathepsin K inhibitor 56 MAGE A3 56 Nasdaq PARD 56 ponatinib 56 masitinib 56 cetuximab Erbitux R 56 pharmacodynamic properties 56 GSK # 56 diabetic nephropathy 56 Vilazodone 56 vivo efficacy 56 pralatrexate 56 dextromethorphan quinidine 56 EndoTAG TM 56 satraplatin Phase 56 Acadia Pharmaceuticals 56 SABCS 56 Cotara 56 highly selective adenosine 56 bevirimat 56 HGS# 56 antitumor effects 56 Viramidine 56 selective androgen receptor modulators 56 NASDAQ BPAX 56 cMET 56 Septin 9 56 BENLYSTA ® 56 immune modulation 56 Tamibarotene 56 T DM1 56 Albuferon TM 56 CRME 56 ARRY # 56 PEG INTRON 56 INCY 56 Onrigin 56 DAVANAT 56 humanized monoclonal 56 radiation sensitizer 56 APTIVUS 56 NS5b 56 Lenocta 56 Chemophase 56 VEGF Trap 56 Phase IIb trial 56 partial agonist 56 Reolysin 56 ZYBRESTAT TM 56 HIV protease inhibitor 56 Androxal TM 56 potent antitumor activity 56 Lu AA# 56 RPRX 56 ISTODAX ® 56 dose escalation Phase 56 ARIKACE ™ 56 cabozantinib 56 Prodarsan ® 56 CBLI 56 ISENTRESS 56 Zavesca R 56 CDK inhibitor 56 HDACi 56 Preclinical studies suggest 56 CVac 56 dasatinib Sprycel ® 56 survivin 56 GLPG# 56 PEP# [003] 56 Tavocept 56 AMRN 56 cell lymphoma CTCL 56 Tranzyme 56 JAK inhibitors 56 NVA# 56 sulodexide 56 mGluR5 negative 56 pharmacodynamic PD 56 gastrointestinal stromal tumors 56 Trofex 56 isoform selective 56 eltrombopag 56 XL# XL# XL# XL# 56 HIV integrase inhibitor 56 imatinib Gleevec ® 56 trastuzumab Herceptin ® 56 T#I [002] 56 Phase IIb Clinical Trial 56 ISTODAX 56 VRUS 56 Solazed TM 56 iobenguane 56 PHX# 56 Aurora kinase inhibitor 56 Tasimelteon 56 ALNY 56 Valortim R 56 immunomodulating 56 Rigel Pharmaceuticals 55 Granulocyte Colony Stimulating Factor 55 Marqibo TM 55 immunotherapeutic vaccine 55 HCV Genotype 55 Pirfenidone 55 telomerase therapeutic 55 luteinizing hormone releasing 55 BNVI 55 sargramostim 55 poly ADP ribose polymerase 55 brivanib 55 ENZN 55 veltuzumab 55 Sunesis Pharma 55 Urocidin 55 ErbB3 55 SERMs 55 viral kinetic 55 Corlux 55 gastrointestinal stromal tumors GIST 55 administered subcutaneously 55 AZD# 55 non nucleoside HCV 55 EnVivo 55 BCR ABL inhibitors 55 metastatic RCC 55 ZGEN 55 retapamulin 55 VeriStrat 55 CBLC# 55 anidulafungin 55 Fx #A 55 dose cohort 55 NASDAQ REGN 55 Allos Therapeutics ALTH 55 Clofarabine 55 gefitinib 55 subcutaneously administered 55 EPCT 55 BIOD 55 TLR9 agonist 55 CANCIDAS 55 Pegylated Interferon 55 RPTP 55 SUTENT 55 mg/m2 dose 55 LXRX 55 Potent Antiviral Activity 55 Presents Preclinical Data 55 MTP inhibitor 55 regorafenib 55 Hedgehog pathway inhibitor 55 TNF Tumor Necrosis Factor 55 RH1 55 Allovectin 7 ® 55 Tolerability 55 ADXS 55 cancer immunotherapies 55 MVA BN R 55 Phase #/#a 55 Clolar ® 55 antisense 55 DYAX 55 CINOD 55 ACZ# 55 Bremelanotide 55 docetaxel Taxotere R 55 oncology therapeutics 55 AMEX RNN 55 KSP inhibitors 55 Dasatinib 55 CRTX 55 Icatibant 55 anti PlGF 55 PI3K/Akt pathway inhibitor 55 afatinib 55 ABII 55 ALTH 55 DB# [003] 55 Randomized Phase II 55 SNT MC# 55 tumor xenograft models 55 diarrhea predominant irritable 55 Hana Biosciences 55 chronic eosinophilic leukemia 55 ocular formulation 55 NP2 Enkephalin 55 Arcalyst 55 rFIXFc 55 Talactoferrin 55 HCD# [002] 55 trabectedin 55 aurora kinase 55 Chemokine 55 Defibrotide 55 Ixabepilone 55 relapsed SCLC 55 dasatinib Sprycel 55 Vectibix panitumumab 55 MOZOBIL 55 GSK# [002] 55 Ostarine 55 RezularTM 55 ACTEMRA TM 55 Presents Preclinical 55 Herceptin trastuzumab 55 BARACLUDE R 55 GTOP 55 gemcitabine Gemzar 55 maturation inhibitor 55 ADAGIO study 55 MAXY 55 preclinical pharmacokinetic 55 TG# [003] 55 imatinib mesylate 55 pegylated 55 TACI Ig 55 JAK2 55 injectable formulation 55 BRIM3 55 recurrent NSCLC 55 Safinamide 55 Belinostat 55 hepatitis C HCV